MEDB-85. Transcriptional complexes as resistance drivers to BET inhibition

BET-bromodomain inhibition (BETi) is a promising therapeutic strategy to target MYC-driven cancers, including Group 3 medulloblastoma, a deadly childhood brain tumor. We have shown that BET inhibitors exhibit preclinical efficacy against MYC¬-amplified medulloblastoma, providing motivation to evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Boynton, Adam, Lupien, Leslie, Kumbhani, Rushil, Gionet, Gabrielle, Chacon, Madison, Goodale, Amy, Root, David, Keshishian, Hasmik, Robinson, Margaret, Carr, Steven, Bandopadhayay, Pratiti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Medulloblastoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164907/
http://dx.doi.org/10.1093/neuonc/noac079.459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164907/
http://dx.doi.org/10.1093/neuonc/noac079.459

Ejemplares similares